Lever­ag­ing Can­cer Biol­o­gy for Ther­a­peu­tic Inno­va­tion: Clin­i­cal and Dis­cov­ery Advances at Ryvu

Ryvu Ther­a­peu­tics is a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny advanc­ing a broad and dif­fer­en­ti­at­ed oncol­o­gy port­fo­lio designed to address high-unmet med­ical needs by tar­get­ing key mech­a­nisms in can­cer biol­o­gy, from dys­reg­u­lat­ed kinas­es to syn­thet­ic lethal­i­ty and pre­ci­sion med­i­cine plat­forms. Our pipeline com­pris­es both inno­v­a­tive clin­i­cal can­di­dates and dis­cov­ery pro­grams that exem­pli­fy nov­el approach­es to treat­ing chal­leng­ing malignancies.

At the fore­front of our clin­i­cal efforts is romaci­clib (RVU120), a first-in-class, oral­ly bioavail­able selec­tive CDK8/CDK19 inhibitor that mod­u­lates tran­scrip­tion­al pro­grams dri­ving can­cer cell sur­vival. Romaci­clib is being eval­u­at­ed across mul­ti­ple Phase II stud­ies, with focus on relapsed or refrac­to­ry acute myeloid leukemia (AML) and myelofi­bro­sis, where encour­ag­ing sig­nals of activ­i­ty and a good safe­ty pro­file have been observed. Oth­er clin­i­cal stud­ies are inves­ti­gat­ing romaci­clib in low­er-risk myelodys­plas­tic syn­dromes and pedi­atric medulloblastoma.

In par­al­lel, dapolsert­ib (MEN1703/SEL24), a dual PIM/FLT3 kinase inhibitor licensed to the Menar­i­ni Group, is pro­gress­ing in Phase II devel­op­ment in dif­fuse large B‑cell lym­phoma (DLB­CL).

Beyond these clin­i­cal assets, Ryvu’s ONCO Prime dis­cov­ery plat­form sup­ports the dis­cov­ery of nov­el pre­ci­sion tar­gets in CRC, TNBC and lung can­cers. Sep­a­rate­ly, Ryvu is advanc­ing ADC pro­grams that incor­po­rate inno­v­a­tive pay­loads, there­by broad­en­ing the range of poten­tial future therapies.

Togeth­er, these pro­grams reflect Ryvu’s com­mit­ment to advanc­ing pre­ci­sion oncol­o­gy by inte­grat­ing deep bio­log­i­cal insights with trans­la­tion­al sci­ence, fos­ter­ing col­lab­o­ra­tions that accel­er­ate the deliv­ery of impact­ful ther­a­pies for patients.